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Human Liver Tumors in Relation to
Steroidal Usage
by G. H. Barrows* and W. M. Christopherson*
Since 1973 a number of investigators have reported an association between liver neoplasia and
steroid usage. Through referral material we have examined the histology of over 250 cases of hepa-
tic neoplasia, most in patients receiving steroid medications. The majority have been benign, pre-
dominantly focal nodular hyperplasia (55%) and hepatocellular adenoma (39%). The average age
was 31.4 years; 83% had significant steroid exposure with an average duration of 71 months for fo-
cal nodular hyperplasia and 79.6 months for hepatocellular adenoma. The type of estrogenic agent
was predominantly mestranol; however, during the period mestranol was the most frequently used
synthetic steroid. A distinct clinical entity of life threatening hemorrhage from the lesion occurred
in 31% of patients with hepatocellular adenoma and 9% of patients with focal nodular hyperplasia.
Recurrence of benign tumors has occurred in some patients who continued using steroids and re-
gression has been observed in patients who had incomplete tumor removal but discontinued steroid
medication. Medial and intimal vascular changes have been present in a large number of the benign
tumors. The relationship of these vascular changes to oncogenesis is unclear, but similar lesions
have been described in the peripheral vasculature associated with steroid administration. A number
of hepatocellular carcinomas have also been seen. Of significance is the young age of these patients
and lack of abnormal histology in adjacent nonneoplastic liver. A striking number of the malignant
hepatocellular tumors have been of the uncommon type described as "eosinophillic hepatocellular
carcinoma with lamellar fibrosis." The epidemiology of liver lesions within this series is difficult to
assess, since the material has been referred from very diverse locations.
Introduction
Since 1973, an apparent association between be-
nign liver tumors and steroid administration has
been widely publicized. Although Baum (1) first
drew widespread attention to the association with a
report describing seven cases of "benign hepato-
mas," other authors had previously reported cases
with steroid association (2,3). By 1977 over 500 re-
ports associating liver tumors with steroid use had
appeared in the literature, most by case reports and
small series (4). The frequency of case reports has
diminished over the past few years, since the associ-
ation is now common knowledge, yet controversy
continues regarding the type of tumors and their re-
lationship to steroids. The infrequency with which
these tumors occur has made it difficult for patholo-
gists to develop a first-hand knowledge of the
histology of these lesions (5). For this reason, histo-
logic review of a large number of cases with refer-
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ence to etiologic factors seemed worthwhile. We
have had the opportunity to study in detail the his-
tology of over 250 cases of hepatic tumors, most in
patients receiving steroids. This presentation re-
views the characteristic features of the lesions col-
lected in this series and data regarding the first 201
cases (6).
Material and Methods
We have accessioned histologic material and case
histories of liver neoplasms since 1973 and have or-
ganized this material into a small registry. Cases
have been furnished by pathologists and clinicians
over a wide geographic area. In addition to a histo-
logic review with a uniform set of criteria, we have
collected as many related data as possible including
patient age, medications, clinical and laboratory
findings and exposure to other known risk factors.
Results
It has been possible to categorize the tumors into
three major types: focal nodular hyperplasia (FNH),BARROWS AND CHRISTOPHERSON
hepatocellular adenoma (HCA) and hepatocellular
carcinoma (HCC). Focal nodular hyperplasia typi-
cally has a central scar and coarsely nodular appear-
ance (Fig. 1). In most cases, FNH lacks encapsula-
tion, although this is not a reliable gross characteris-
tic. The lesions varied in size from 2 to 15 cm, and
two distinct types are distinguishable. "Active le-
sions," which have a more varied gross appearance,
often contain large regenerating nodules up to sev-
eral centimeters in diameter. They frequently
contain areas of necrosis and hemorrhage, and scar-
ring is often minimal. Inactive lesions, more typical
of the classical description of FNH, contain dense
central scarring and fibrous trabeculae; hemorrhage
and necrosis are absent. We believe such tumors
represent involution or maturing of the more active
lesions. They have at times been referred to as ha-
martomas (7).
The microscopic appearance of FNH is character-
istic. Fibrosis with aggregates of bile duct epitheli-
um intervenes between relatively normal hepato-
cytes (Fig. 2). There is no characteristic arrange-
ment of the cells in relationship to venous or portal
structures. The hepatocytes may contain glycogen
or fat. Large nodules may be formed which are sep-
arated by fibrous septa. The presence of bile duct
epithelium is a sine qua non of focal nodular hyper-
plasia. In large active examples of FNH, adequate
sampling is essential, since the central portions of
larger lesions may lack the characteristic areas of
scarring with the adjacent exuberant proliferation
of bile duct epithelium.
HCA (Fig. 3) is sufficiently characteristic that it
can usually be distinguished from focal nodular hy-
perplasia by its gross characteristics. HCA tends to
be of soft consistency and is yellow to dark brown.
The lesions vary in size from 1 cm to 22 cm. On sec-
tioning, the tumor at times has a variegated appear-
ance due to necrosis, hemorrhage, and at times, bile
staining. The fibrous trabeculae and scarring, so
characteristic of FNH is absent. While HCA has
usually been described as encapsulated, it often is
not in steroid users. This suggests that in some
cases of HCA may represent monomorphic hyper-
plasia. In some cases, intrahepatic hemorrhage is
present (Fig. 4). The cells of HCA also resemble nor-
mal hepatocytes butusually havemore nuclear varia-
tion. Nucleoli are usually present and are small and
FIGURE 1. Focal nodular hyperplasla: typical gross appearance.
202LIVER NEOPLASMAND STEROID USAGE
Lr adenoma: typical gross appearance.
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)atocellular adenoma with intrahepatic hemorrhage.
regular. Most tumors have spare mitotic activity
but binucleate cells are present. The cells are ar-
rayed in rather disorganized sheets, or in an acinic
pattern. In contrast to FNH, there are usually nu-
merous turn walled vascular channels, and most im-
portantly no bile duct epithelium (Fig. 5).
HCC varies extensively in its gross appearance.
All have been predominantly hepatocellular al-
though two examples also contained cholangiolar
elements. A distinctive subtype "eosinophilic hepa-
tocellular carcinoma" accounted for 10 of the 23
cases (Fig. 6). This subtype has been uncommon in
other reported series of hepatocellular carcinoma
(8,9). Of significance is the lack of abnormal histol-
ogy in the adjacent liver in the steroid related ma-
lignancies. Although 17 of the 23 cases were moder-
ately well differentiated, there were no long-term
survivors.
Characteristic vascular changes are found within
some benign tumors, particularly FNH (Fig. 7).
Smooth muscle proliferation and intimal thickening
at times with occlusive thrombosis occurred in
branches of the hepatic artery and tributaries of the
portal vein.
A striking finding in both benign and malignant
hepatocellular tumors is the presence of small, eo-
sinophilic inclusions. They are PAS-positive, dias-
tase-resistant and by immunoperoxidase technique
have been shown to contain a, antitrypsin (10). Elec-
tron microscopy reveals them to be granular mater-
ial within the endoplasmic reticulum. Small deposits
are nonmembrane-bound, whereas large deposits
are membrane-bound and found associated with
smooth endoplasmic reticulum.
The age distribution of patients (Table 1) was sim-
ilar in both FNH, and HCA with an average of 31.4
years and a range from 14 to 57 years (Table 2). The
majority of patients took oral contraceptives (83%)
with an average of 74.7 months exposure. An addi-
tional 3% were exposed to equine conjugated estro-
gens (Premarin) and 3% were pregnant or immedi-
ately post partum. Thus, a total of 89% of patients
had significant steroid exposure, endogenous or ex-
ogenous. As in other studies, the predominant agent
used among contraceptive users was mestranol.
Tumors were multiple in over 20% of women
with benign tumors (Table 3). In most cases, there
were only two or three separate tumors, but occa-
sionally livers contained a large number. At times,
inaccessibility of some of the multiple lesions pre-
cluded surgical resection. Those which have been
unresectable have provided valuable insight of the
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FIGURE 5. Hepatocellular adenoma: note thin-walled vessel and acinar organization of hepatocytes. H & E. 250 x .
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FIGURE 6. Eosinophilic hepatocellular carcinoma with lamellarBARROWS AND CHRISTOPHERSON
FIGURE 7. Focal nodular hyperplasia: steroid-related vascular changes. H & E. 130 x .
Table 1. Benign liver tumors (n = 178).
Age, yr
% Average Range
FNH 55 32.3 19-52
HCA 40 30.2 14-55
Unclassified 5 30.3 27-47
natural history of steroid related lesions, since their
future course can be monitored.
The signs and symptoms among patients with be-
nign tumors were available in most cases (Table 4).
A distinct clinical syndrome of shock and abdominal
pain occurred in some patients. This was associated
with intratumoral hemorrhage or tumor rupture
and hemoperitoneum. The syndrome occurred more
frequently in women with HCA. An additional num-
ber of patients presented with abdominal mass.
Nearly one-half the cases of FNH were found inci-
dentally during an unrelated surgical procedure.
Mortality associated with both FNH and HCA
was confined to patients with tumor rupture and he-
moperitoneum (Table 5). Despite incomplete re-
moval of tumors, in some cases serious sequellae
have not yet been reported.
The hepatocellular carcinomas in this series oc-
curred almost exclusively among young women
Table 3. Incidence of multiple tumors
in steroid-associated lesions.
Number of
tumors
2-3
4-5
Many
Total
FNI
(n =
15.
3.i
2.(
20.4
Percent of cases
H HCA
98) (n = 71)
3 16.9
1 2.8
D 4.2
4 22.5
with an average age of 30.6 years, and an age range
of 17-57. Of 23 patients, 20 had significant steroid
exposure, and there was no historical or histologic
evidence of other known risk factors (Table 6). The
prognosis has been poor. Of 21 patients who have
follow-up available, 20 died with metastases and the
other patient is terminally ill.
Discussion
The association between liver tumors and ster-
oids does not prove the steroids to be causative.
Some recent studies have been useful in estab-
lishing perspective. Klatskin (11) compiled signs and
symptoms from case reports of 234 patients with
FNH and 138 patients with HCA, not known to be
receiving steroids. Since the majority of these cases
Table 2. Benign liver tumors: steroid association (n = 169).
Contraceptive Conjugated Pregnancy, None, Unknown,
steroids, % estrogen, % % 0/ %
Focal nodular hyperplasia 82.7 4.1 1.0 5.1 8.2
Hepatocellular adenoma 83.1 1.4 5.6 7.0 2.8
Total 82.8 3.0 3.0 5.3 5.9
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Table 4. Benign liver tumors signs and symptoms.
Hemoperi-
Pain, % titis, °/ Mass, % Incidental, %
FNH (n = 98) 24.5 9.2 16.3 46.9
HCA (n = 71) 24.0 31.0 36.6 5.6
X2 0.006 13.1 9.1 33.7
p 0.93 <0.001 <0.001 <0.001
Table 5. Mortality in benign liver tumors.
Mortality, % No./total
HCA 7.0 (5/ 17)
FNH 2.0 (2/ 98)
Both 4.2 (7/169)
occurred before synthetic steroids were used for
contraception, it is probably safe to assume that
most did not receive exogenous steroids (11). Sixty
percent occurred in women of child-bearing age. Al-
though this documents that tumors may arise with-
out exogenous steroids, it also suggests that they
are related to natural hormonal variations. In fur-
ther support of this observation is the occurrence of
tumors during pregnancy or in the immediate post-
partum period (12,13). Additional case reports have
associated liver neoplasms with androgenic-anabolic
steroids (14,15) and adrenal carcinoma (7).
The behavior of tumors incompletely resected
also supports their dependency on steroids. Recur-
rence and enlargement of the tumors have been re-
ported in cases where steroids have been continued
(16). Regression of unresected tumors has also been
documented when steroid therapy has been
discontinued (6,11,16-18).
There is no clear implication of any specific type
of steroid. While contraceptive steroids have been
closely associated with these tumors, it should be
remembered they are also by far the most com-
monly prescribed agents. As in other studies, mes-
tranol was the most common estrogen in this series.
Edmondson and associates have interpreted this to
imply increased risk with this agent (19). As Sturte-
vant points out, however, if Edmondson's data are
corrected for patterns of contraceptive product use
at the time of occurrence, the observed association
of mestranol use is probably related to marketing
patterns ofvarious contraceptive agents (20).
The frequent occurrence of tumor rupture and
intra-abdominal hemorrhage in the patients re-
ceiving steroids also suggests a hormonal relation-
ship. Comparing the two compiled historical series
from Klatskin with the cases presented here, there
is highly significant increase (p < 0.001) in the occur-
rence of hemoperitoneum in steroid users compared
to nonusers (Table 7). The question of bias in re-
Table 6. Hepatocellular carcinoma
associated with steroids (n = 23).
Medication Number Average duration of use
Oral contraceptives 17 56.6 months
Conjugated estrogen 1 Long-term
Postpartum 2 -
None 3
Table 7. Comparison ofclinical signs: steroid-associated
tumors compared to reported case without steroid usage.
No
Sign Steroidsa steroidsb x2 p
HCA Hemoperitoneum 31.0% 15.2% 13.0 <0.001
Mass or hepatomegaly 36.6 37.0 0.06 0.80
Pain 24.0 19.6 0.21 0.64
FNH Hemoperitoneum 9.2% 0.4% 18.1 <0.001
Mass or hepatomegaly 6.3 12.4 0.91 0.34
Pain 24.4 7.3 18.6 <0.001
a Adapted from Christopherson et al. (6). HCA, n = 71;
FNH, n = 98.
b Adapted from Klatskin (11). HCA, n = 138; FNH, n =
234.
porting only steroid liver tumors was examined by
Rooks et al in a case controlled study based on the
patients accessioned in the AFIP Registry (21).
These authors demonstrated the increased risk as-
sociated with steroid usage was the same before
and after 1972 when the association between liver
tumors and contraceptive steroids became widely
known. They estimated the magnitude of risk of
HCA to be 3.4/100,000 in women receiving contra-
ceptive steroids and 1.0 to 1.3/million in nonsteroid
users (21).
No predisposing factors for the development of
benign liver tumors has yet been identified. The
presence of a,-antitrypsin inclusions in these lesions
initially raised concern of a possible association with
a,-antitrypsin deficiency. However, Palmer in a
small series of cases did not find any significant phe-
notype of a,-antitrypsin deficiency (10).
The vascular changes associated with benign
liver tumors in steroid users, particularly FNH, ap-
pear to be characteristic for these lesions (12,22).
While there is no proof that these are primary, they
are similar to lesions appearing in experimental ani-
mals receiving steroids. These vascular lesions also
bear a striking resemblance to lesions reported in
patients with reproductive steroid exposure (23).
Liver function tests and a-fetoprotein studies
have been nondiagnostic when available in this
series and also in the cases reported by Klatskin
(11).
The hepatoceilular carcinomas pose an area of
great concern. Since malignant tumors of the liver
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are much more common than benign lesions, the as-
sociation between hepatocellular carcinoma and
steroids is more tenuous. Of interest is the absence
of hepatic fibrosis, a lack of cirrhoses and the young
age in these patients. This is in marked contrast to
reported series, where hepatocellular carcinoma is
more frequent in males, occurs in middle-aged pa-
tients and is associated with cirrhoses in up to 90%
of cases. Patients with HCC in this series had a dis-
mal prognosis despite the prevalence of a reported
favorable subtype (8,9). This subtype appears to
have a less frequent association with cirrhosis than
other carcinomas (9), which is in keeping with the
absence of associated liver pathology in this series.
Unlike the reported cases of HCC in males re-
ceiving anabolic steroids, most of these cases devel-
oped distant metastases (22).
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